Literature DB >> 16422903

Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel.

Kevin L Billups1, Alan J Bank, Harin Padma-Nathan, Stuart Katz, Richard Williams.   

Abstract

INTRODUCTION: Cardiovascular disease and its related comorbidities are associated with significant morbidity and mortality and affect a disproportionately large number of African Americans and Hispanics. The prevalence of cardiovascular disease is increasing worldwide, which underscores the urgency to improve methods of prevention and early detection. AIM: To develop a risk assessment and management algorithm for primary care patients with erectile dysfunction (ED) that facilitates diagnosis, early intervention, and prevention of cardiovascular disease.
METHODS: The Minority Health Institute (MHI) convened an Expert Advisory Panel of cardiologists and urologists to design a new practice model algorithm that uses ED as a clinical tool for early identification of men with systemic vascular disease. A draft of the algorithm was presented at a national symposium and comments from symposium participants were considered in the development of the final algorithm. MAIN OUTCOME MEASURES AND
RESULTS: Erectile dysfunction is common and has long been considered a secondary complication of cardiovascular disease, diabetes, hypertension, and dyslipidemia. However, a growing body of evidence challenges this view, suggesting instead that ED is an early manifestation of atherosclerosis and a precursor to systemic vascular disease. Endothelial dysfunction is the etiologic factor linking ED and cardiovascular disease.
CONCLUSIONS: The recognition of ED as an early sign of systemic cardiovascular disease offers an opportunity for prevention, particularly in high-risk and underserved minority populations. The MHI algorithm stipulates that all men 25 years old and older regardless of sexual dysfunction complaints should be asked about ED. The presence of ED should prompt an aggressive assessment for cardiovascular risk and occult systemic vascular disease.

Entities:  

Mesh:

Year:  2005        PMID: 16422903     DOI: 10.1111/j.1743-6109.2005.20104_1.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  28 in total

1.  Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group.

Authors:  Lisa B Kenney; Laurie E Cohen; Margarett Shnorhavorian; Monika L Metzger; Barbara Lockart; Nobuko Hijiya; Eileen Duffey-Lind; Louis Constine; Daniel Green; Lillian Meacham
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

2.  Occurrence of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome in patients with abdominal obesity. Where is a sufficient level of testosterone?

Authors:  Juraj Fillo; Jan Breza; Michaela Levčíkova; Jan Luha; Anna Vachulova; Štefan Durdík; Peter Labaš
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

Review 3.  Bicycle riding, perineal trauma, and erectile dysfunction: data and solutions.

Authors:  Irwin Goldstein; Alan L Lurie; John P Lubisich
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

Review 4.  Emerging role for TNF-α in erectile dysfunction.

Authors:  Fernando S Carneiro; Robert Clinton Webb; Rita C Tostes
Journal:  J Sex Med       Date:  2010-12       Impact factor: 3.802

5.  Changes in erectile dysfunction over time in relation to Framingham cardiovascular risk in the Boston Area Community Health (BACH) Survey.

Authors:  Shona C Fang; Raymond C Rosen; Joseph A Vita; Peter Ganz; Varant Kupelian
Journal:  J Sex Med       Date:  2014-10-08       Impact factor: 3.802

6.  Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses.

Authors:  Mary P Fitzgerald; Carol L Link; Heather J Litman; Thomas G Travison; John B McKinlay
Journal:  Eur Urol       Date:  2007-03-19       Impact factor: 20.096

Review 7.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

Review 8.  [Erectile dysfunction: indicator of end-organ damage in cardiovascular patients].

Authors:  Magnus Baumhäkel; Nils Schlimmer; Mario T Kratz; Michael Böhm
Journal:  Med Klin (Munich)       Date:  2009-04-15

9.  Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction - RELY-II.

Authors:  Luc Valiquette; Francesco Montorsi; Stephen Auerbach
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

Review 10.  Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

Authors:  Steven G Chrysant
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.